Hereditary Hemorrhagic Telangiectasia (HHT) Center
This grant supports clinical partnerships, better diagnosis, and a patient data registry to improve care and outcomes for people with Hereditary Hemorrhagic Telangiectasia (HHT).
Funder: Health Resources and Services Administration
Due Dates (Anticipated): July 2026 (Full application deadline, projected)
Funding Amounts: Up to $2,900,000 total; one award anticipated; project period and annual ceiling not specified, but prior cycles suggest a 1-year award
Summary: Supports a center to reduce illness and death from Hereditary Hemorrhagic Telangiectasia (HHT) through expanded care, clinician support, and a patient data registry.
Key Information: This is a forecasted opportunity; dates and details may change when the official NOFO is released.
Description
This opportunity will fund a center dedicated to reducing morbidity and mortality associated with Hereditary Hemorrhagic Telangiectasia (HHT), a rare genetic disorder. The program aims to:
- Partner with a clinical center to expand access to and coordination of care for HHT patients,
- Develop and implement innovative strategies to help clinicians identify and diagnose HHT cases,
- Create a de-identified, aggregate patient data registry to improve understanding of HHT and its treatment outcomes.
The program is designed to support research, clinical care coordination, and data infrastructure that can drive improved outcomes for individuals affected by HHT.
